Q-omics provides the consensus-scored PLEKHA3P1 profile across patient tissues and cancer cell-line models. PLEKHA3P1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PLEKHA3P1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, PLEKHA3P1 RNA expression shows 16,654 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, KIRC, and GBM as cancer lineages where PLEKHA3P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLEKHA3P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLEKHA3P1 survival associations across molecular data types. PLEKHA3P1 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLEKHA3P1 RNA expression–survival associations across cancer types. High PLEKHA3P1 expression shows unfavorable associations in DLBC, but favorable associations in LUAD, UCEC, SKCM, UCS and ESCA. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PLEKHA3P1 RNA expression.
This table summarizes PLEKHA3P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PLEKHA3P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLEKHA3P1 shows lower tumor expression in LUSC, KICH, BRCA, UCEC and LUAD and higher tumor expression in KIRC. The KIRC box plot shows higher PLEKHA3P1 RNA expression in tumor versus normal tissue (log2 FC = +0.390, t-test p < 0.001).
This table shows molecular features associated with PLEKHA3P1 in patient tissues and cancer cell lines. In patient samples, PLEKHA3P1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
